Insmed Ownership
INSM Stock | USD 77.77 1.22 1.59% |
Shares in Circulation | First Issued 1999-03-31 | Previous Quarter 173.7 M | Current Value 179 M | Avarage Shares Outstanding 46.9 M | Quarterly Volatility 48 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Insmed |
Insmed Stock Ownership Analysis
About 99.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 5.57. Insmed Inc had not issued any dividends in recent years. The entity had 1:10 split on the 3rd of March 2011. Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey. Insmed operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 613 people. To learn more about Insmed Inc call MBA JD at 908 977 9900 or check out https://www.insmed.com.Besides selling stocks to institutional investors, Insmed also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Insmed's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Insmed's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Insmed Quarterly Liabilities And Stockholders Equity |
|
Insmed Insider Trades History
Less than 1% of Insmed Inc are currently held by insiders. Unlike Insmed's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Insmed's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Insmed's insider trades
Insmed Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Insmed is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Insmed Inc backward and forwards among themselves. Insmed's institutional investor refers to the entity that pools money to purchase Insmed's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Rtw Investments, Llc | 2024-12-31 | 3 M | Ameriprise Financial Inc | 2024-12-31 | 2.9 M | Fidelity International Ltd | 2024-12-31 | 2.6 M | William Blair Investment Management, Llc | 2024-12-31 | 2.4 M | Alliancebernstein L.p. | 2024-12-31 | 2.4 M | Macquarie Group Ltd | 2024-12-31 | 2.3 M | Franklin Resources Inc | 2024-12-31 | 2.2 M | T. Rowe Price Investment Management,inc. | 2024-12-31 | 2 M | Pictet Asset Manangement Sa | 2024-12-31 | 2 M | Vanguard Group Inc | 2024-12-31 | 18.2 M | Blackrock Inc | 2024-12-31 | 16 M |
Insmed Inc Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Insmed insiders, such as employees or executives, is commonly permitted as long as it does not rely on Insmed's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Insmed insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Insmed Outstanding Bonds
Insmed issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Insmed Inc uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Insmed bonds can be classified according to their maturity, which is the date when Insmed Inc has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Insmed Corporate Filings
F4 | 5th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 24th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10K | 20th of February 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
14th of February 2025 Other Reports | ViewVerify |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Insmed Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Insmed. If investors know Insmed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Insmed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.57) | Revenue Per Share | Quarterly Revenue Growth 0.248 | Return On Assets | Return On Equity |
The market value of Insmed Inc is measured differently than its book value, which is the value of Insmed that is recorded on the company's balance sheet. Investors also form their own opinion of Insmed's value that differs from its market value or its book value, called intrinsic value, which is Insmed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Insmed's market value can be influenced by many factors that don't directly affect Insmed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Insmed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Insmed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Insmed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.